Treatment of laryngopharyngeal and lingual hereditary angioedema with bradykinin-B2-receptor-antagonist icatibant

被引：0

|

作者：

Bas, M.

Greve, J.

Kojda, G.

Bier, H.

Hoffmann, K.

机构：

[1] Univ Hosp Dusseldorf, Dusseldorf, Germany

[2] Univ Hosp Dusseldorf, Inst Pharmacol & Clin Pharmacol, Dusseldorf, Germany

来源：

ALLERGY | 2007年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

引用

收藏

页码：95 / 95

页数：1

相关论文

共 50 条

[31] Icatibant, a Selective Bradykinin B2 Receptor Antagonist Used in Hereditary Angioedema Due to C1 Inhibitor Deficiency
Bork, K.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) : AB165 - AB165
[32] Icatibant acetate -: Treatment of hereditary angioedema -: Agent for liver cirrhosis -: Antiasthmatic drug -: Treatment of osteoarthritis pain -: Bradykinin B2 antagonist
Sorbera, LA
Fernández-Forner, D
Bayés, M
DRUGS OF THE FUTURE, 2006, 31 (02) : 101 - 106
[33] Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema (vol 363, pg 532, 2010)
Cicardi, M.
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (15): : 1486 - 1486
[34] A case series about the treatment of hereditary angioedema due to C1 inhibitor deficiency with icatibant, a selective bradykinin B2 receptor antagonist
Bork, K.
ALLERGY, 2010, 65 : 455 - 455
[35] Treatment of patients with acute attacks of hereditary angioedema due to C1-INH deficiency with the bradykinin B2 receptor-antagonist Icatibant
Farkas, H.
Varga, L.
Szeplaki, G.
Temesszentandrasi, G.
Jakab, L.
Fekete, B.
Fust, G.
Karadi, L.
ALLERGY, 2008, 63 : 474 - 475
[36] Self-Administration Of a Novel Subcutaneous Bradykinin B2 Receptor Antagonist, Icatibant (Firazyr®), As An Effective Treatment Option In Patients With Hereditary Angioedema (HAE)
Santucci, Stephanie
Hoang Pham
Harrison, Rachel
Yang, William H.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB31 - AB31
[37] Treatment of angiotensin-converting enzyme inhibitor-related angioedema with the bradykinin B2 receptor antagonist icatibant
Schmidt, Peter W.
Hirschl, Michael M.
Trautinger, Franz
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 63 (05) : 913 - 914
[38] Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial
Lumry, William R.
Li, H. Henry
Levy, Robyn J.
Potter, Paul C.
Farkas, Henriette
Moldovan, Dumitru
Riedl, Marc
Li, Hongbin
Craig, Timothy
Bloom, Bradley J.
Reshef, Avner
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (06) : 529 - 537
[39] A novel therapeutic concept for the treatment of acute angioedema attacks in hereditary angioedema patients: multiple successful treatments even in severe swelling attacks with the bradykinin-B2 receptor antagonist Icatibant
M Bas
J Greve
G Kojda
H Bier
T Hoffmann
Critical Care, 10 (Suppl 1):
[40] Safety Evaluation of Icatibant, a Selective Bradykinin B2 Receptor Antagonist Used in Hereditary Angioedema Due to C1 Inhibitor Deficiency
Staubach, P.
Bork, K.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S100 - S100

← 1 2 3 4 5 →